Longer (TA)n repeat but not A49T and V89L polymorphisms in SRD5A2 gene may confer prostate cancer risk in South Indian men

Journal of Andrology

Volumn 30, Issue 6, 2009, Pages 703-710

  Rajender, Singh ^a,b   Vijayalakshmi, Krishnaswamy ^c   Pooja, Singh ^a   Madhavi, Sakhamuri ^b   Paul, Solomon F D ^c   Vettriselvi, V ^c   Shroff, Sunil ^c   Singh, Lalji ^b   Thangaraj, Kumarasamy ^b  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

^c SRI RAMACHANDRA UNIVERSITY   (India)

Author keywords

5 reductase; Benign prostatic hyperplasia; Dihydrotestosterone; South Indian population; Testosterone

Indexed keywords

ALANINE; GENOMIC DNA; LEUCINE; REPETITIVE DNA; STEROID 5ALPHA REDUCTASE; THREONINE; VALINE;

ADULT; AGED; ALLELE; ARTICLE; CANCER PATIENT; CANCER RISK; CONTROLLED STUDY; DNA POLYMORPHISM; GENETIC RISK; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INDIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SEQUENCE ANALYSIS; SRD5A2 GENE;

AGED; AGED, 80 AND OVER; ALLELES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INDIA; MALE; MIDDLE AGED; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RISK; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 70449599769     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.108.007377     Document Type: Article

References (38)

1. Akalu A, Dlmajian DA, Highshaw RA, Nichols PW, Reichardt JK. Somatic mutations at the SRD5A2 locus encoding prostatic steroid 5α-reductase during prostate cancer progression. J Urol. 1999;161:1355-1358. (Pubitemid 29426156)
2. Coffey DS. In: Lepor H, Lawson RK eds. The Molecular Biology of the Prostate. Philadelphia, PA: Saunders; 1993;28-56.
3. Cussenot O, Azzouzi AR, Nicolaiew N, Mangin P, Cormier L, Fournier G, Valeri A, Cancel-Tassin G. Low-activity V89L variant in SRD5A2 is associated with aggressive prostate cancer risk: an explanation for the adverse effects observed in chemoprevention trials using 5-alpha-reductase inhibitors. Eur Urol. 2007;52:1082-1087. (Pubitemid 47337033)
4. Febbo PG, Kantoff PW, Platz EA, Casey D, Batter S, Giovannucci E, Hennekens CH, Stampfer MJ. The V89L polymorphism in the 5-reductase type 2 gene and risk of prostate cancer. Cancer Res. 1999;59:5878-5881. (Pubitemid 30004943)
5. Geller J, de la Vega DJ, Albert JD, Nachtsheim DA. Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer. J Clin Endocrinol Metab. 1984;58:36-40. (Pubitemid 14220514)
6. Giwercman YL, Abrahamsson PA, Giwercman A, Gadaleanu V, Ahlgren G. The 5alpha-reductase type II A49T and V89L high-activity allelic variants are more common in men with prostate cancer compared with the general population. Eur Urol. 2005;48:679-685. (Pubitemid 41278596)
7. Hayes VM, Severi G, Padilla EJ, Morris HA, Tilley WD, Southey MC, English DR, Sutherland RL, Hopper JL, Boyle P, Giles GG. 5Alpha-reductase type 2 gene variant associations with prostate cancer risk, circulating hormone levels and androgenetic alopecia. Int J Cancer. 2007;120:776-780. (Pubitemid 46175396)
8. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev. 2004;25:276-308.
9. Hsing AW, Chen C, Chokkalingam AP, Gao YT, Dightman DA, Nguyen HT, Deng J, Cheng J, Sesterhenn IA, Mostofi K, Stanczyk FZ, Reichardt JKV. Polymorphic markers in the SRD5A2 gene and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomark Prev. 2001;10:1077-1082. (Pubitemid 32959155)
10. Jaffe JM, Malkowicz SB, Walker AH, MacBride S, Peschel R, Tomaszewski J, Van Arsdalen K, Wein AJ, Rebbeck TR. Association of SRD5A2 genotype and pathological characteristics of prostate tumors. Cancer Res. 2000;60:1626-1630. (Pubitemid 30183434)
11. Jemal A, Thun MJ, Ries LA, Howe HL, Weir HK, Center MM, Ward E, Wu XC, Eheman C, Anderson R, Ajani UA, Kohler B, Edwards BK. Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst. 2008;100:1672-1694.
12. Kantoff PW, Febbo PG, Giovannucci E, Krithivas K, Dahl DM, Chang G, Hennekens CH, Brown M, Stampfer MJ. A polymorphism of the 5-reductase gene and its association with prostate cancer: a case-control analysis. Cancer Epidemiol Biomark Prev. 1997;6:189-192. (Pubitemid 27118466)
13. Latil AG, Azzouzi R, Cancel GS, Guillaume EC, Cochan-Priollet B, Berthon PL, Cussenot O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer. 2001;92:1130-1137. (Pubitemid 32861661)
14. Lunn RM, Bell DA, Mohler JL, Taylor JA. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis. 1999;20:1727-1731.
15. Makridakis NM, di Salle E, Reichardt JK. Biochemical and pharmacogenetic dissection of human steroid 5alpha-reductase type II. Pharmacogenetics. 2000;10:407-413.
16. Makridakis NM, Ross RK, Pike MC, Crocitto LE, Kolonel LN, Pearce CL, Henderson BE, Reichardt JK. Association of mis-sense substitution in SRD5A2 gene with prostate cancer in African-American and Hispanic men in Los Angeles, USA. Lancet. 1999;354:975-978.
17. Mononen N, Ikonen T, Syrjakoski K, Matikainen M, Schleutker J, Tammela TLJ, Koivisto PA, Kallioniemi OP. A missense substitution A49T in the steroid 5-reductase gene (SRD5A2) is not associated with prostate cancer in Finland. Br J Cancer. 2001;84:1344-1347. (Pubitemid 32522102)
18. Nam RK, Toi A, Vesprini D, Ho M, Chu W, Harvie S, Sweet J, Trachtenberg J, Jewett MA, Narod SA. V89L polymorphism of type-2, 5-reductase enzyme gene predicts prostate cancer presence and progression. Urology. 2001;57:199-205. (Pubitemid 32065856)
19. Ntais C, Polycarpou A, Ioannidis JP. SRD5A2 gene polymorphisms and the risk of prostate cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev. 2003;12:618-624. (Pubitemid 36899841)
20. Nwosu V, Carpten J, Trent JM, Sheridan R. Heterogeneity of genetic alterations in prostate cancer: evidence of the complex nature of the disease. Hum Mol Genet. 2001;10:2313-2318. (Pubitemid 32998847)
21. Onen IH, Ekmekci A, Eroglu M, Polat F, Biri H. The association of 5alpha-reductase II (SRD5A2) and 17 hydroxylase (CYP17) gene polymorphisms with prostate cancer patients in the Turkish population. DNA Cell Biol. 2007;26:100-107. (Pubitemid 46363875)
22. Parkin DM, Whelan SL, Ferlaym J, Raymond L, Young J. Cancer Incidence in Five Continents. Vol 2. Lyon, France: IARC; 1997.
23. Rajender S, Singh L, Thangaraj K. Phenotypic heterogeneity of mutations in androgen receptor gene. Asian J Androl. 2007;9:147-179. (Pubitemid 46416577)
24. Reichardt JK, Makridakis N, Henderson BE, Yu MC, Pike MC, Ross RK. Genetic variability of the human SRD5A2 gene: implications for prostate cancer risk. Cancer Res. 1995;55:3973-3975.
25. Ross RK, Bernstein L, Lobo RA, Shimizu FZ, Stanczyk FZ, Pike MC, Henderson BE. 5-Reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet. 1992;339:887-889.
26. Salam MT, Ursin G, Skinner EC, Dessissa T, Reichardt JK. Associations between polymorphisms in the steroid 5-alpha reductase type II (SRD5A2) gene and benign prostatic hyperplasia and prostate cancer. Urol Oncol. 2005;23:246-253. (Pubitemid 40961936)
27. Sobti RC, Onsory K, Al-Badran AI, Kaur P, Watanabe M, Krishan A, Mohan H. CYP17, SRD5A2, CYP1B1, and CYP2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol. 2006;25:287-294. (Pubitemid 43830442)
28. Soderstrom T, Wadelius M, Andersson SO, Johansson JE, Johansson S, Granath F, Rane A. 5Alpha-reductase 2 polymorphisms as risk factors in prostate cancer. Pharmacogenetics. 2002;12:307-312.
29. Srinivas V, Mehta H, Amin A, Choudary R, Gadgil N, Ravishanker D, Phadke AG. Carcinoma of the prostate - state at initial presentation. Int Urol Nephrol. 1995;27:419-422.
30. Thangaraj K, Joshi MB, Reddy AG, Gupta NJ, Chakravarty B, Singh L. CAG repeat expansion in the androgen receptor gene is not associated with male infertility in Indian populations. J Androl. 2002;23:815-818. (Pubitemid 36300971)
31. Thangaraj K, Singh L, Reddy AG, Rao VR, Sehgal SC, Underhill PA, Pierson M, Frame IG, Hagelberg E. Genetic affinities of the Andaman Islanders, a vanishing human population. Curr Biol. 2003;13:86-93. (Pubitemid 36154335)
32. Thigpen AE, Silver RI, Guileyardo JM, Casey ML, McConnell JD, Russell DW. Tissue distribution and ontogeny of steroid 5-reductase isozyme expression. J Clin Invest. 1993;92:903-910.
33. van der Kwast TH, Schalken J, Ruizeveld de Winter JA, van Vroonhoven CC, Mulder E, Boersma W, Trapman J. Androgen receptors in endocrine-therapy- resistant human prostate cancer. Int J Cancer. 1991;48:189-193.
34. Wilbert DM, Griffin JE, Wilson JD. Characterization of the cytosol androgen receptor of the human prostate. J Clin Endocrinol Metab. 1983;56:113-120. (Pubitemid 13212316)
35. Wu AH, Whittemore AS, Kolonel LN, John EM, Gallagher RP, West DW, Hankin J, The CZ, Dreon DM, Paffenbarger RS Jr. Serum androgens and sex-hormone binding globulins in relation to lifestyle factors in older African-American, white, and Asian men in the United States and Canada. Cancer Epidemiol Biomark Prev. 1995;4:735-741.
36. Yamada Y, Watanabe M, Murata M, Yamanaka M, Kubota Y, Ito H, Katoh T, Kawamura J, Yatani R, Shiraishi T. Impact of genetic polymorphisms of 17-hydroxylase cytochrome P-450 (CYP17) and steroid 5α-reductase type II (SRD5A2) genes on prostate cancer risk among the Japanese population. Int J Cancer. 2001;92:683-686. (Pubitemid 32385710)
37. Ziada A, Rosenblum M, Crawford ED. Benign prostatic hyperplasia: an overview. Urology. 1999;53:1-6.
38. Zubiaga AM, Belasco JG, Greenberg ME. The nonamer UUAUUUAUU is the key AU-rich sequence motif that mediates mRNA degradation. Mol Cell Biol. 1995;15:2219-2230.